Cost-effectiveness of ximelagatran for stroke prevention.
Publication
, Journal Article
Perret-Guillaume, C; Wahl, D
Published in: JAMA
June 15, 2005
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
June 15, 2005
Volume
293
Issue
23
Start / End Page
2860 / 2861
Location
United States
Related Subject Headings
- Warfarin
- Stroke
- Quality-Adjusted Life Years
- Prodrugs
- Humans
- General & Internal Medicine
- Cost-Benefit Analysis
- Benzylamines
- Azetidines
- Atrial Fibrillation
Citation
APA
Chicago
ICMJE
MLA
NLM
Perret-Guillaume, C., & Wahl, D. (2005). Cost-effectiveness of ximelagatran for stroke prevention. JAMA, 293(23), 2860–2861. https://doi.org/10.1001/jama.293.23.2860
Perret-Guillaume, Christine, and Denis Wahl. “Cost-effectiveness of ximelagatran for stroke prevention.” JAMA 293, no. 23 (June 15, 2005): 2860–61. https://doi.org/10.1001/jama.293.23.2860.
Perret-Guillaume C, Wahl D. Cost-effectiveness of ximelagatran for stroke prevention. JAMA. 2005 Jun 15;293(23):2860–1.
Perret-Guillaume, Christine, and Denis Wahl. “Cost-effectiveness of ximelagatran for stroke prevention.” JAMA, vol. 293, no. 23, June 2005, pp. 2860–61. Pubmed, doi:10.1001/jama.293.23.2860.
Perret-Guillaume C, Wahl D. Cost-effectiveness of ximelagatran for stroke prevention. JAMA. 2005 Jun 15;293(23):2860–2861.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
June 15, 2005
Volume
293
Issue
23
Start / End Page
2860 / 2861
Location
United States
Related Subject Headings
- Warfarin
- Stroke
- Quality-Adjusted Life Years
- Prodrugs
- Humans
- General & Internal Medicine
- Cost-Benefit Analysis
- Benzylamines
- Azetidines
- Atrial Fibrillation